At Takara Bio, "contributing to the health of mankind through the development of revolutionary biotechnologies such as gene therapy" is our corporate philosophy. Guided by this philosophy, Takara Bio is dedicated to the development of biotechnology-related products and technologies as an R&D-oriented organization. In an industry dependent on constant technical innovation, our management policy is to conduct R&D aggressively while returning profits to our shareholders by increasing corporate value through improved business results. To achieve this, we are striving to expedite our decision making and to improve our business efficiency.
The Board of Directors consists of seven members (including one external director) who meet whenever necessary in addition to the regular monthly Board meetings. The Board makes decisions on important issues concerning the management of the Company and its management policies as well as overseeing execution of the Company's business. One external director has been designated as an independent director in accordance with the rules stipulated by the Tokyo Stock Exchange (TSE).
The Company has adopted an auditing system, and two of our four Audit & Supervisory Board (ASB) members are external to the Company. The Company has established an internal auditing department comprising three personnel. The Company endeavors to enhance internal control through a system in which the ASB members conduct audits while coordinating with the internal auditing department as required.
Our parent company is Takara Holdings Inc., which owns 60.92% of the voting rights as of the end of March 2014. Takara Holdings' policy in managing its group companies is to seek to maximize the corporate value of the whole Takara Group while enabling each and every member corporation of the Takara Group to maintain its uniqueness and independence. Since our business of biotechnology requires highly advanced expertise and quick decision making, we are especially unique and independent in the Takara Group. While we report the decisions made at our Board meetings and other issues to the parent company, no prior approval is required in order to execute our decisions.
Corporate Governance System